Caris Life Sciences to Highlight Research at 2025 SGO Annual Meeting on Women's Cancer
Five studies, including two oral presentations, demonstrate the critical role of Caris' comprehensive molecular profiling in gynecological cancer
IRVING, Texas, March 11, 2025 /PRNewswire/ -- Caris Life Sciences ® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (Caris POA) will collectively present five studies across multiple gynecological tumor types at the Society of Gynecologic Oncology's (SGO) Annual Meeting on Women's Cancer, March 14-17, 2025, in Seattle, Washington. The findings demonstrate the power of Caris' comprehensive clinico-genomic database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.
'Caris and our POA collaborators are proud to present five studies at this year's SGO Annual Meeting highlighting the critical role of molecular profiling and biomarkers in personalizing treatment for gynecological cancers,' said Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD. 'By utilizing our comprehensive clinico-genomic database, we have improved the understanding of tumor biology and shown how specific molecular characteristics affect prognosis and treatment efficacy. This work exemplifies our dedication to advancing precision medicine and optimizing oncology treatment strategies.'
Oral Presentations
Oral Featured Poster
Genomic and Immunohistochemical Characterization of NSMP Endometrial Cancer: A Novel Approach to Estrogen Receptor Positivity
Oral Featured Poster Session II: Multiple Ways to Make an IMPACT
March 15: 4:23-4:26 PM PST
Posters
GPR171, a Prognostic Marker of Improved Survival in Cervix Cancer – A Deep South Consortium in Oncology (DSCO) Project
Poster Session | March 16, 2:00 – 3:30 PM PST
Comparison of Breast and Gastric HER2 Immunohistochemistry (IHC) Scoring Criteria in the Assessment of Endometrial Carcinoma
Poster Session | March 16, 2:00 – 3:30 PM PST
Poster and abstract summaries highlighting this research will be available onsite at Caris' booth #416. The full abstracts will be available on the Caris website following the presentation.
The Caris POA includes 96 cancer centers, academic institutions, research consortia and healthcare systems, including 47 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research. Caris and POA members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multimodal database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides a differentiated platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition, and we value our employees as much as we do our patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. To learn more, please visit CarisLifeSciences.com.
214.294.5606
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
MetasTx Secures NCI Grant to Enable the Advancement of Dual-Track Strategy Against Metastatic Prostate Cancer
PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- MetasTx, LLC, a biotechnology company focused on preventing the metastasis of solid tumor cancers – like prostate, breast and skin, announced today it has received a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH). The award supports the company's development of a diagnostic tool to predict metastatic potential in early-stage prostate cancer (PCa). The award reflects confidence in MetasTx's multichannel strategy to detect and interrupt cancer metastasis. Combining pharmacologic and diagnostic innovation, MetasTx aims to transform how clinicians identify and treat patients at risk of metastatic disease - beginning with PCa. 'This federal grant affirms our approach to addressing one of oncology's most complex challenges,' said Harvey D. Homan, CEO of MetasTx. 'Our companion diagnostic program has the potential to deliver earlier, more precise insights to clinicians and ultimately improve patient outcomes.' About the NCI-Funded Diagnostic Program The funded project - 'Epithelial-Mesenchymal Transition Signature Markers (EMTsm) with Machine Learning-Based Analysis as a Predictor of Metastatic Prostate Cancer'— proposes to identify the relevant signature biomarkers, and the development of methods for their early detection for diagnostic purposes. This proof of principle project is expected to be completed by Q2 2026. Success with this would lead to development of a Companion Diagnostic that will be used to identify patients with PCa who are likely to need aggressive treatment to prevent metastasis, and could streamline enrollment into future clinical trials, to reduce costs and significantly speed up bringing our new drugs to FDA for approval. Parallel Pharmacologic Development The MetasTx drug development program is focused on novel molecules that were designed and synthesized in the laboratory of Dr. David Crich, PhD. Patent applications have been filed by the University of Georgia Research Foundation from whom MetasTx plans to license the I P for these molecules. The two best compounds are being tested and analyzed through a cascade of biochemical and cellular assays for efficacy and safety, under the direction of MetasTx, with plans in place for studies that will support a New Drug Application and likely progression to the First-In-Human (Phase 1/2a) clinical study by late 2027. Generative AI will be employed to discover improved next generation compounds. This integrated diagnostic-therapeutic approach positions MetasTx for clinical and commercial impact. The initial clinical focus is on the more than 3 million men in the U.S with PCa, of which approximately 2 million are under active surveillance for early PCa — representing a potential $11.5 billion market opportunity. Capital Efficiency and Investor Opportunity MetasTx's business model emphasizes capital efficiency, strategic outsourcing, and a clear path to acquisition. MetasTx currently is seeking to raise $500,000 in a pre-seed convertible note financing round to support ongoing operations and continuation of the drug development program, with a $2 million seed equity financing round to follow shortly. About MetasTx MetasTx, LLC is a clinical-stage company developing a platform to detect and block the spread of cancer from solid tumors. Backed by a seasoned leadership team and scientific advisors, MetasTx integrates molecular diagnostics and drug discovery to address metastasis at its root. For more information, visit or contact HarveyDHoman@ Media Contact:Cindi SuteraCindiS@ & CommunicationsMetasTx, LLCSign in to access your portfolio
Yahoo
4 days ago
- Yahoo
Mom Convinced Daughter with Cancer to Reject Chemotherapy, Family Claims. She Died 7 Months Later
The sons of prominent U.K. conspiracy theorist Kate Shemirani are blaming their sister's death on their mother's anti-science views Gabriel and Sebastian Shemirani told the BBC news program Panorama that their sister Paloma died from non-Hodgkin lymphoma after refusing chemotherapy for the illness, a decision they believe was influenced by their mother Kate has blamed Paloma's death on a cover-up, and in response to the Panorama episode, posted on social media, "Let them all fall on their swords. My silence has been for a reason our silence as her parents has been for a reason"The sons of prominent anti-vaxxer and conspiracy theorist Kate Shemirani have blamed the former nurse for the death of their sister, her daughter Paloma, who died in 2024 after refusing chemotherapy for cancer. In a Monday, June 23, interview with the BBC news program Panorama, Gabriel and Sebastian Shemirani said that while growing up in the English town of Uckfield, their mother believed that the Sept. 11 terrorist attack on the World Trade Center was an "inside job" and that the Sandy Hook school shooting was staged. When their mother was diagnosed with breast cancer in 2012, the ordeal fortified her anti-science views, they said — and while Kate underwent surgery to remove the cancer, she credited her recovery to juices and coffee enemas. Although Gabriel and Sebastian stopped speaking with their mother after their parents split, Paloma — Gabriel's twin — remained in contact with her. As Sebastian told the BBC, 'Paloma's strategy was to appease, to be sweet, to try and win the love that she hadn't been granted earlier.' When Paloma was diagnosed with non-Hodgkin lymphoma in late 2023, she was given a positive prognosis — 80% chance of survival — with chemotherapy; without it, the BBC reports, the cancer could be fatal. However, BBC reported that once Kate visited her daughter in the hospital, Paloma decided against chemotherapy, opting to treat her cancer with Gerson therapy, which involves juices, supplements, and enemas, and is not an approved treatment for cancer, the National Cancer Institute notes. No studies have been done that support the belief that it's an effective cancer treatment, according to the NCI. Paloma's mother supervised her care, the BBC reports; in July 2024, she was put on life support following a heart attack. A few days later, Paloma had died at 23 years old. Kate responded to Paloma's death by proclaiming in posts on X that she had been murdered and that her death had been covered up. 'Medicine is a lie and what we once believed to be healthcare is now a homicide service,' she wrote, later calling her daughter's death 'one big massive manslaughter case.' Sebastian placed the blame for his sister's death squarely on his mother, and told the BBC, 'My sister has passed away as a direct consequence of my mum's actions and beliefs. And I don't want anyone else to go through the same pain or loss that I have.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. PEOPLE has reached out to Kate for a comment. An inquest — the term for a legal investigation in the U.K. — into Paloma's death is scheduled for next month. Responding to an X user who claimed the BBC fabricated their claims about Paloma's death, Kate wrote, 'Let them all fall on their swords. My silence has been for a reason our silence as her parents has been for a reason. The documents do not lie and when we ready we will show the world because it affects everyone what is being done.' Read the original article on People
Yahoo
4 days ago
- Yahoo
Five University of Colorado Cancer Center Advancements That Changed the Game for Patients
As the CU Cancer Center celebrates its 40th anniversary, here are five ways it helped to change detection and treatment of the disease. AURORA, Colo., June 24, 2025 /PRNewswire/ -- The University of Colorado Cancer Center this year celebrates its 40th anniversary, highlighting significant advances in research and innovations that include new therapies, treatments and insights into cancer prevention. "For 40 years, the CU Cancer Center has been the cornerstone of cancer research, innovation and care in Colorado and the Rocky Mountain region," says CU Anschutz Chancellor Donald Elliman. "We're not only delivering world-class care today – we're bringing new possibilities into reach and redefining the cancer treatment of the future." The CU Cancer Center, founded in 1985, became a National Cancer Institute-designated cancer center in 1988 under the leadership of its founding director, Paul Bunn, MD. In 1997, it had the further distinction of being named one of 57 NCI Comprehensive Cancer Centers. The "comprehensive" designation recognizes the center's strengths in basic, translational, clinical and population science research, as well as leadership and resources devoted to community outreach and engagement and cancer research training and education. Here are five innovations that helped make the CU Cancer Center part of the worldwide cancer conversation. Multidisciplinary clinics It can take an army of specialists to treat a cancer patient, and in the early days of the CU Cancer Center, that meant multiple appointments on multiple days with specialists who may or may not have been aligned on a treatment plan. That changed in 2012, when Richard Schulick, MD, MBA, became chair of the CU Department of Surgery. Schulick brought with him the concept of a multidisciplinary clinic for pancreatic and biliary cancers in which a patient comes in for one day and is seen by multiple specialists — including surgical oncologists, medical oncologists, radiation oncologists, pathologists, dietitians and genetic counselors. They then meet that same day to develop a comprehensive treatment plan. When Schulick became director of the CU Cancer Center in 2018, he expanded the multidisciplinary clinics. There are now clinics for 12 types of cancer. "It was incredible to suddenly have all these doctors come together to give me answers," says patient Val Beck, who was treated for colorectal cancer at the CU Cancer Center in 2023. "They never lied to me. They told me that my type of cancer was scary, and they said it was going to be hard. But they also said they were going to ensure I received the best treatment possible." A new treatment for acute myeloid leukemia Thanks in large part to early work by CU Cancer Center researchers Craig Jordan, PhD, and Daniel Pollyea, MD, MS, patients with the blood cancers acute myeloid leukemia (AML) and myelodysplastic syndrome have a new treatment option that has fewer side effects and has been shown to increase longevity. In 2020, the Food and Drug Administration granted regular approval to the drug venetoclax (Venclexta), in combination with a low-dose chemotherapy treatment, for the treatment of AML in older adults who are unfit for intensive chemotherapy. The drug works by targeting and inhibiting the Bcl-2 protein, a key component of leukemia stem cells. Of 31 evaluable patients treated with venetoclax in a 2018 clinical trial conducted by Pollyea and Jordan, 20 experienced complete remission, while eight had a complete response but with continued low blood counts. The FDA granted the drug preliminary approval based on those clinical trials and a subsequent randomized study. Pollyea and Jordan still are researching the drug to determine how it could be even more effective, including new and upcoming studies on its effects in younger populations as well as research to tackle both upfront and post-treatment resistance. "Some of our hypotheses about how we could use venetoclax weren't necessarily part of the conventional wisdom five years ago," Pollyea says. "It's exciting to see how many of our theories were correct, and to see how others in the hematology community have built out parts of the story that are very complementary and exciting. We're all learning from each other." Lowering the screening age for colorectal cancer After an alarming rise in colorectal cancer in people younger than 50, the United States Preventive Services Task Force in 2021 lowered the recommended screening age for the cancer from 50 to 45 for people at normal risk. One of the key figures behind the move was Andrea Dwyer, program director of the Colorado Cancer Screening Program at the CU Cancer Center, who worked alongside the American Cancer Society to expand the screening population. "The change in the guideline is going to take several years to fully catch on with people in the way we need it to, but we're already starting to see some people start their screening at age 45," Dwyer says. "We still have a lot of work to do on awareness of the need to start screening earlier. Colorectal cancer does happen among young adults, even teenagers, and we don't know why." Cell-based immune therapies Though many cancers are still effectively treated with chemotherapy and radiation, some cancers — especially blood cancers — have seen a revolution with treatments using the patient's own immune cells to attack cancer cells. The CU Cancer Center is at the forefront of this evolving science. Tumor-infiltrating lymphocyte therapy, for example — which is being studied by CU Cancer Center researchers including Eduardo Davila, PhD — involves surgically removing tumor tissue from a patient's body and extracting activated T cells from the tissue. The cells are multiplied in the lab, then reinfused into the patient's body to attack tumors. The CU Cancer Center also is a national leader in chimeric antigen receptor T cell (CAR T) therapy, a powerful treatment in which a patient's immune cells are removed from their body, taken to a lab and genetically engineered to become fighter cells, then injected back into the patient, where they seek out and destroy cancer cells. One of the leaders in this effort is CU Cancer Center member Terry Fry, MD, executive director of the Gates Institute, a translational research institute on the CU Anschutz Medical Campus that produces CAR T and other cellular therapies for research. Gates recently launched a clinical trial of a CAR for pediatric patients with relapsed or refractory pre B-cell acute lymphoblastic leukemia (B-ALL). Elsewhere on campus, M. Eric Kohler, MD, PhD, and Catherine Danis, PhD, recently published research on a next-generation CAR T therapy called ALA-CART (adjunctive LAT-activating CAR-T cells), which optimizes CAR-T cells to more effectively eliminate cancer cells, including those that have been able to hide from traditional CAR-T cells. The therapy also is being studied at the Flint Animal Cancer Center at Colorado State University, one of the CU Cancer Center's clinical partners. A trial launched in 2023 at Flint is testing the effectiveness of CAR T treatment on naturally occurring osteosarcoma in pet dogs. "These are cells that can potentially live in your body for months or even years," says Steven Dow, DVM, PhD, "The cells eradicate the cancerous tumor with the aim to make sure it doesn't recur." Testing for gene mutations in lung cancer Not all lung cancers are created equal, and researchers at the CU Cancer Center's Thoracic Oncology Research Initiative helped to pioneer the practice of testing for genetic mutations within lung cancer cells to determine which patients are likely to respond to specific medications — in some cases a single daily oral medication that allows someone diagnosed with lung cancer to enjoy a better quality of life. Research into fusions and mutations by CU Cancer Center members Robert Doebele, MD, PhD, Marileila Garcia, PhD, and D. Ross Camidge, MD — as well as early research in the field by Paul Bunn, MD, the cancer center's first director — has helped thousands of lung cancer patients worldwide. "We're fortunate that in Colorado, we were one of the early adopters of doing routine molecular testing of our lung cancer patients, to put them into different buckets based on the mutations in their cancer," Camidge says. "That allowed us to say, 'OK, there are five people in front of us, and they all have lung cancer, but really, they have different subtypes of lung cancer, and they need different treatments.' When you personalize that treatment, you start to really get transformative control of the cancer." About the University of Colorado Anschutz Medical CampusThe University of Colorado Anschutz Medical Campus is a world-class medical destination at the forefront of transformative science, medicine, education and patient care. The campus encompasses the University of Colorado health professional schools, more than 60 centers and institutes, and two nationally ranked independent hospitals - UCHealth University of Colorado Hospital and Children's Hospital Colorado - that treat more than two million adult and pediatric patients each year. Innovative, interconnected and highly collaborative, the University of Colorado Anschutz Medical Campus delivers life-changing treatments, patient care and professional training and conducts world-renowned research fueled by over $705 million in research grants. For more information, visit Contact: Laura Kelley, University of Colorado Anschutz Medical Campus View original content to download multimedia: SOURCE University of Colorado Anschutz Medical Campus Sign in to access your portfolio
